دورية أكاديمية
Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer.
| العنوان: | Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer. |
|---|---|
| المؤلفون: | Tan JSH; J Tan, Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Tay TKY; T Tay, Singapore General Hospital Department of Pathology, Singapore, Singapore., Ong EHW; E Ong, National Cancer Centre Singapore, Singapore, Singapore., Fehlings M; M Fehlings, Immunoscape, Singapore, Singapore., Tan DS; D Tan, National Cancer Centre Singapore, Singapore, Singapore., Sukma NB; N Sukma, Department of Pathology, Singapore General Hospital, Singapore, Singapore., Chen EX; E Chen, Department of Pathology, Singapore General Hospital, Singapore, Singapore., Sng JH; J Sng, Department of Pathology, Singapore General Hospital, Singapore, Singapore., Yip CSP; C Yip, National Cancer Centre Singapore, Singapore, Singapore., Lim KH; K Lim, Department of Pathology, Singapore General Hospital, Singapore, Singapore., Lim DW; D Lim, National Cancer Centre Singapore, Singapore, Singapore., Iyer NG; N Iyer, National Cancer Centre Singapore, Singapore, Singapore., Hwang JSG; J Hwang, Department of Pathology, Singapore General Hospital, Singapore, Singapore., Chua MLK; M Chua, National Cancer Centre Singapore, Singapore, Singapore., Ang MK; M Ang, National Cancer Centre Singapore, Singapore, Singapore. |
| المصدر: | European thyroid journal [Eur Thyroid J] 2024 Jan 01. Date of Electronic Publication: 2024 Jan 01. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Bioscientifica Ltd Country of Publication: England NLM ID: 101604579 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2235-0802 (Electronic) Linking ISSN: 22350640 NLM ISO Abbreviation: Eur Thyroid J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : [Bristol] : Bioscientifica Ltd. Original Publication: Basel : S. Karger |
| مستخلص: | Objectives Anaplastic thyroid cancer (ATC) is an aggressive disease associated with poor outcomes and resistance to therapies. Our study aim was to evaluate the activity of a combinatorial regimen of sandwich sequencing of pembrolizumab immunotherapy and hypofractionated radiotherapy (RT). Methods In this case series, patients with ATC received hypofractionated RT (QUAD-shot) and intravenous pembrolizumab 200mg every 3-4 weeks. Pembrolizumab was continued until disease progression or up till 24 months. Concurrent Lenvatinib treatment was allowed. Primary endpoint was best overall response (BOR) and progression-free survival (PFS). Additionally, we performed immune profiling of circulating T cells in a responder to investigate the immune response to our combinatorial treatment. Results At median follow-up of 32.6 months (IQR: 26.4-38.8), of a cohort of 5 patients, BOR was 80%; with 2 complete responses (CR) and 2 partial responses (PR). Patients who achieved CR remained disease-free at last follow-up. Median PFS was 7.6 months (IQR: 6.2-NR), and 1-year PFS and overall survival rate was 40% (95% CI: 13.7-100) for both. Treatment was well-tolerated, with mostly grade 1-2 adverse events. Immune profiling of one partial responder revealed an increase in activated CD4 and CD8 T cells post-QUAD-shot RT, which was further enhanced during the maintenance phase of pembrolizumab. Conclusions Herein, we reported a case series of 5 patients with ATC, with 2 long-term survivors who were treated with surgical debulking followed by QUAD-shot RT and pembrolizumab, possibly due to synergy of local and systemic treatments in activating anti-tumour immunogenic cytotoxicity. This regimen warrants further investigation in a larger cohort of patients. |
| References: | Lancet Oncol. 2023 Feb;24(2):175-186. (PMID: 36681089) Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. (PMID: 29615459) J Clin Invest. 2016 Mar 1;126(3):1052-66. (PMID: 26878173) Hum Mol Genet. 2015 Apr 15;24(8):2318-29. (PMID: 25576899) Int J Cancer. 2019 May 1;144(9):2266-2278. (PMID: 30515783) Endocr Relat Cancer. 2008 Dec;15(4):1069-74. (PMID: 18719091) J Clin Endocrinol Metab. 2017 Jun 1;102(6):1943-1950. (PMID: 28324060) Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945) N Engl J Med. 2018 Dec 13;379(24):2342-2350. (PMID: 30280658) J Mol Diagn. 2006 Nov;8(5):540-3. (PMID: 17065421) J Clin Oncol. 2018 Jan 1;36(1):7-13. (PMID: 29072975) J Clin Endocrinol Metab. 2016 Jul;101(7):2863-73. (PMID: 27045886) Cancer. 2021 May 15;127(10):1553-1567. (PMID: 33620731) Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):70-80. (PMID: 32544576) J Clin Oncol. 2021 Jul 20;39(21):2359-2366. (PMID: 33961488) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) Oncotarget. 2021 Oct 12;12(21):2223-2226. (PMID: 34676054) Cancer. 2017 May 1;123(9):1653-1661. (PMID: 28026871) Thyroid. 2021 Jul;31(7):1076-1085. (PMID: 33509020) Cancer Treat Rev. 2022 Apr;105:102361. (PMID: 35231870) Oncology (Williston Park). 2012 Apr;26(4):398, 401, 406. (PMID: 22655532) Thyroid. 2020 Sep;30(9):1384-1389. (PMID: 32292131) Oncoimmunology. 2016 Mar 30;5(6):e1168556. (PMID: 27471646) J Clin Oncol. 2020 Aug 10;38(23):2620-2627. (PMID: 32364844) Lancet Oncol. 2021 Apr;22(4):450-462. (PMID: 33794205) Future Oncol. 2019 Mar;15(7):717-726. (PMID: 30638399) Lancet. 2014 Jul 26;384(9940):319-28. (PMID: 24768112) Clin Cancer Res. 2018 Oct 15;24(20):5058-5071. (PMID: 29898992) N Engl J Med. 2015 Feb 12;372(7):621-30. (PMID: 25671254) Thyroid. 2018 Jun;28(6):739-747. (PMID: 29774792) Lancet Oncol. 2020 Apr;21(4):531-540. (PMID: 32105622) N Engl J Med. 2020 Aug 27;383(9):825-835. (PMID: 32846061) Am J Transl Res. 2019 Sep 15;11(9):5888-5896. (PMID: 31632557) |
| تواريخ الأحداث: | Date Created: 20240105 Latest Revision: 20240228 |
| رمز التحديث: | 20240228 |
| مُعرف محوري في PubMed: | PMC10895326 |
| DOI: | 10.1530/ETJ-23-0144 |
| PMID: | 38181007 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-0802 |
|---|---|
| DOI: | 10.1530/ETJ-23-0144 |